Asia’s yen for U.S. biotech could hit a speed bump

Asian investors have been pouring billions into U.S. biotech over the past few years, but they could be headed for a bureaucratic headache that discourages future bets.

Yesterday, the Trump administration unveiled new rules that will impose enhanced scrutiny on foreign investment in “critical” industries including biotech.

The way the provision is worded, any deal that results in a U.S. company sharing nonpublic information is subject to federal review, which all but guarantees that every overseas biotech deal will undergo scrutiny.

Read more.